NCT05597800 (LUNGVIR) is a Phase 2 clinical trial of Nivolumab and Ipilimumab in NSCLC Stage IV, sponsored by Universita di Verona.

Who is sponsoring NCT05597800?

NCT05597800 is sponsored by Universita di Verona.

What drugs are being tested in NCT05597800?

Interventions in NCT05597800: Nivolumab and Ipilimumab.

What condition does NCT05597800 study?

NCT05597800 studies NSCLC Stage IV, HIV, HBV, HCV, Long COVID.

Is NCT05597800 still recruiting?

NCT05597800 is currently not yet recruiting. Last updated 28 October 2022.

Last reviewed 2022-10-28 · How we verify

NCT05597800: LUNGVIR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome

Not yet recruiting Phase 2 Last updated 28 October 2022

What this trial tests

Phase 2 trial testing Nivolumab and Ipilimumab in NSCLC Stage IV in 105 participants. Not yet recruiting.

Timeline

1 February 2023

Primary endpoint
31 December 2026

30 March 2027

Quick facts

Lead sponsor	Universita di Verona
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	105
Start date	1 February 2023
Primary completion	31 December 2026
Estimated completion	30 March 2027
Sites	1 location across Italy

Drugs / interventions tested

Nivolumab and Ipilimumab (nivolumab-and-ipilimumab) — full drug profile →

Conditions studied

NSCLC Stage IV — all drugs for NSCLC Stage IV →
HIV — all drugs for HIV →
HBV — all drugs for HBV →
HCV — all drugs for HCV →

Sponsor

Universita di Verona — full company profile →

Who can join

Adults 18 to 75, any sex, with NSCLC Stage IV or HIV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study type: Phase 2 - Interventional Trial Number of patients to be enrolled: 105 Participating countries: Italy Study drugs: nivolumab and ipilimumab Cohort A: HBV and HCV patients Cohort B: HIV patients Cohort C: Long COVID syndrome The stratification factors are HBV/HCV positive (cohort A), HIV positive (cohort B), patients with Long Covid syndrome (Cohort C), histology (squamous vs non-squamous histology), and gender (male vs female).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Nivolumab and Ipilimumab

Trials testing the same drug.

NCT04256213 — COL Immunotherapy Before Radiochimio + Ipilimumab · NA · completed
NCT03620123 — A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck · Phase 2 · completed
NCT03526185 — A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes · EARLY_PHASE1 · terminated
NCT02693535 — TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumo · Phase 2 · recruiting

Other recruiting trials for NSCLC Stage IV

Currently open trials in the same condition.

NCT07279402 — TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% · recruiting
NCT06401824 — Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases · Phase 2 · recruiting
NCT06532149 — ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · recruiting
NCT06313541 — Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunothera · Phase 2 · recruiting
NCT06788366 — AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer · recruiting

Other Universita di Verona trials

Trials by the same sponsor.

NCT07393919 — Discontination of Antidepressants in Remitted Depression · Phase 4 · not yet recruiting
NCT07042724 — Exercise and Nutrition on Early-stage NSCLC Outcomes: the STARLighT Study · NA · recruiting
NCT07129954 — Fear of Falling in Muscular Dystrophy · NA · recruiting
NCT07119827 — Personality Traits as a Variable in the Recovery of Patients With Acquired Brain Injury · recruiting
NCT07209306 — WHO Psychological Interventions for Mental Health Outcomes in Migrants Resettled in Italy: the ADVANCE Trial · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05597800 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universita di Verona
Last refreshed: 28 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05597800.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing